ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå ¿¹Ãø - Áö¿ªº° ºÐ¼® : À¯Çü, ¿ëµµ, ±¸ÀÔ Çüź°(2030³â)
North America Eye Drops Market Forecast to 2030 - Regional Analysis - by Type (Antibiotics, Artificial Tears, Hormones, and Others), Application, and Purchase Mode (OTC and Prescription)
»óǰÄÚµå : 1402537
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 87 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,991,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,438,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,885,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº 2022³â 80¾ï 3,088¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2030³â¿¡´Â 122¾ï 8,912¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 5.5%·Î ÃßÁ¤µË´Ï´Ù.

¾È°ú ÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ ºÏ¹Ì Á¡¾È¾à ½ÃÀåÀ» µÞ¹Þħ

½Ã·Â Àå¾Ö·Î À̾îÁö´Â ´ç´¢º´¼º ¸Á¸·Áõ, ³ì³»Àå, ¾È±¸°ÇÁ¶Áõ µî ¾È°ú ÁúȯÀÇ ÀÌȯÀ²Àº ƯÈ÷ ¼±Áø±¹¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °ÇÁ¶ÇÑ ´«Àº ºÒÄè°¨, ÀÚ±Ø ¹× ½Ã°¢ Àå¾Ö¸¦ ÃÊ·¡ÇÏ´Â ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. 2020³â 4¿ù ¹Ì±¹¿¡¼­ ½Ç½ÃÇÑ ¼³¹®Á¶»ç 'National Health and Wellness Survey'¿¡ µû¸£¸é 1,640¸¸ ¸íÀÌ ¾È±¸°ÇÁ¶ÁõÀ¸·Î Áø´ÜµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ 18-34¼¼ÀÇ À¯º´·üÀÌ 2.7% ±ÞÁõÇß´Ù´Â µ¥ÀÌÅ͵µ ÀÖ½À´Ï´Ù. Novaliq GmbH¿¡ µû¸£¸é ÇöÀç ¾à 1700¸¸¸íÀÇ ¹Ì±¹ÀÎÀÌ ¾È±¸°ÇÁ¶ÁõÀ¸·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù.

´ç´¢º´ ¸Á¸·ÁõÀº ¹Ì¼¼ Ç÷°üÀÇ ¸»´Ü ±â°ü Àå¾ÖÀÔ´Ï´Ù. ´ç´¢º´ ¸Á¸·ÁõÀº ºñÁõ½Ä ´ç´¢º´ ¸Á¸·Áõ ´Ü°è¿¡¼­ Áõ½Ä ´ç´¢º´ ¸Á¸·ÁõÀ¸·Î ÁøÇàµË´Ï´Ù. ´ç´¢º´ ¸Á¸·ÁõÀÌ ÁøÇàµÇ¸é ±×¿¡ µû¸¥ ´ç´¢º´ Ȳ¹Ý ºÎÁ¾µµ ºÐ¸íÇØÁú ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹¾È°úȸ°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é 2030³â±îÁö Àü ¼¼°è¿¡¼­ ÃßÁ¤ 1¾ï 9,100¸¸ ¸íÀÌ ´ç´¢º´¸Á¸·Áõ¿¡ °É¸° °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. Medscape¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¾à 70¸¸ ¸íÀÌ Áõ½Ä ´ç´¢º´ ¸Á¸·ÁõÀ» ¾Î°í ÀÖÀ¸¸ç ¸Å³â ¾à 6¸¸ 5,000¸íÀÌ »õ·Ó°Ô ¹ßº´Çϰí ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)°¡ 2022³â¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ¼¼°è ¾à 22¾ï ¸íÀÌ ±Ù°ß ¶Ç´Â ¿ø°ß ½Ã·ÂÀå¾Ö·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù. ½Ã·Â Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀº ¹é³»Àå(¾à 9,400¸¸ °Ç)°ú ±³Á¤µÇÁö ¾ÊÀº ±¼Àý ÀÌ»ó(¾à 8,840¸¸ °Ç)ÀÔ´Ï´Ù. ÀÇ»ç´Â ÀϹÝÀûÀ¸·Î ¾È°ú ÁúȯÀÇ Ä¡·á ¹× ¿¹¹æÀ» À§ÇØ ¾È¾àÀ» ó¹æÇÕ´Ï´Ù. µû¶ó¼­ ¾È°ú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ºÏ¹Ì Á¡¾È¾à ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀå ¹è°æ¿¡´Â ¾È±¸°ÇÁ¶Áõ¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡Çϰí, ³ëÈ­ Àα¸°¡ Áõ°¡Çϰí, ¾È ÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾È°ú Ä¡·á ÀýÂ÷ÀÇ ±â¼ú ¹ßÀüÀÌ ÀÖ½À´Ï´Ù. ¾È±¸°ÇÁ¶ÁõÀº ¹Ì±¹¿¡¼­ ÈçÇÑ Áúº´ÀÌÁö¸¸ Áø´ÜÀÌ ºÒÃæºÐÇÕ´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡´Â ¾È±¸°ÇÁ¶ÁõÀÇ À¯º´·üÀ» ´õ¿í ³ôÀÔ´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ°ü¸®¼¾ÅÍ(CDC)¿¡ µû¸£¸é Ȳ¹Ýº¯¼º, ¹é³»Àå, ´ç´¢º´¼º ¸Á¸·Áõ, ³ì³»Àå µî ³ëÈ­¿¡ µû¸¥ ¾ÈÁúȯÀº ¹Ì±¹¿¡¼­ ½Ç¸í°ú ¾à½ÃÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±âŸ, ¾à½Ã³ª »ç½Ã µîÀÇ ÀϹÝÀûÀÎ ¾ÈÁúȯµµ º¸°íµÇ°í ÀÖ½À´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­ ¹× ÀþÀºÃþÀÌ ±¼Àý ±³Á¤ ¼ö¼úÀ» ¹Þ´Â ºóµµ°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ¾È±¸°ÇÁ¶ÁõÀº 2030³â±îÁö ¹Ì±¹¿¡¼­ 279¸¸¸íÀÇ ³²¼ºÀÌ º´À» ¾ÎÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹Àº ºÏ¹Ì Á¡¾È¾à ½ÃÀå¿¡¼­ °¡Àå Å©°í °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ±¹°¡ÀÔ´Ï´Ù. ÀÌ ³ª¶ó ½ÃÀåÀº »ç¶÷µé »çÀÌ¿¡¼­ ¾È±¸°ÇÁ¶ÁõÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¹Ì±¹¿¡´Â ¾È±¸°ÇÁ¶Áõ¸¦ Ä¡·áÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¡¾È¾à°ú ·»Á Á¦°øÇÏ´Â ±â¾÷ÀÌ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¹Ì±¹¿¡¼­ ºÏ¹Ì Á¡¾È¾à ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀÇ ¼öÀÍ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº À¯Çü, ¿ëµµ, ±¸¸Å ÇüÅÂ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº Ç×»ýÁ¦, Àΰø´«¹°, È£¸£¸ó, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå¿¡¼­´Â Ç×»ýÁ¦ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº ¾ÈÁúȯ, ¾ÆÀÌÄÉ¾î µîÀ¸·Î ±¸ºÐµË´Ï´Ù. ¾ÈÁúȯ ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾ÈÁúȯ ºÎ¹®Àº ¾È±¸°ÇÁ¶Áõ, ³ì³»Àå, ¹é³»Àå µîÀ¸·Î ±¸ºÐµË´Ï´Ù.

±¸¸Å ÇüÅ¿¡ µû¶ó ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº ½ÃÆÇ¾à°ú ó¹æÀüÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ Á¡¾È¾à ½ÃÀå¿¡¼­´Â ó¹æÀü ºÎ¹®ÀÌ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ ¾È¾à ½ÃÀåÀº ¹Ì±¹ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.

AbbVie Inc., Akorn Operating Company LLC, Alcon AG, Bausch & Lomb Inc, Pfizer Inc, Prestige Consumer Healthcare Inc, Rohto Pharmaceutical Co Ltd, Similasan Corp.´Â ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå »óȲ

Á¦5Àå ºÏ¹Ì ¾È¾à ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦6Àå ¾È¾à ½ÃÀå : ºÏ¹Ì ½ÃÀå ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) : À¯Çüº°

Á¦8Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) : ¿ëµµº°

Á¦9Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) : ±¸ÀÔ Çüź°

Á¦10Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) : ±¹°¡º° ºÐ¼®

Á¦11Àå ºÏ¹ÌÀÇ ¾È¾à ½ÃÀå-¾÷°è Á¤¼¼

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦13Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The North America eye drops market is expected to grow from US$ 8,030.88 million in 2022 to US$ 12,289.12 million by 2030. It is estimated to grow at a CAGR of 5.5% from 2022 to 2030.

Rising Prevalence of Ophthalmic Diseases Fuels North America Eye Drops Market

The incidence of ophthalmic diseases such as diabetic retinopathy, glaucoma, and dry eye leading to vision impairment is rising among the population, especially in developed countries. A dry eye is caused by multiple factors that result in discomfort, irritation, and visual disturbance. According to a study, "National Health and Wellness Survey," conducted in the US in April 2020, ~16.4 million people were diagnosed with dry eye. The data also stated that the prevalence had surged by 2.7% among people aged 18-34 years. According to Novaliq GmbH, ~17 million Americans currently suffer from dry eye disease.

Diabetic retinopathy represents microvascular end-organ damage. It progresses from non-proliferative diabetic retinopathy stages to proliferative diabetic retinopathy. As the disease progresses, associated diabetic macular edema may also become apparent. According to an article published by the American Academy of Ophthalmology, it is estimated that by 2030 an estimated 191 million people globally will suffer from diabetic retinopathy. According to Medscape, ~700,000 people in the US suffer from proliferative diabetic retinopathy, with ~65,000 new cases recorded annually.

According to an article published by the World Health Organization (WHO) in 2022, ~2.2 billion people worldwide suffer from near or distant vision impairment. The leading causes of vision impairment are cataracts (~94 million cases) and uncorrected refractive errors (~88.4 million cases). Doctors generally prescribe eye drops for the treatment and prevention of ophthalmic diseases. Hence, the increasing prevalence of ophthalmic diseases is fueling the growth of the North America eye drops market .

North America Eye Drops Market Overview

The North America eye drops market has been segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the rising awareness of dry eye conditions, an increase in the aging population, and technological advancements in eye treatment procedures with the rising incidence of eye disorders. Dry eye disease is a common but underdiagnosed condition in the US. The growing geriatric population further triggers the prevalence of dry eye disease. According to the Centers for Disease Control and Prevention (CDC), age-related eye diseases such as macular degeneration, cataract, diabetic retinopathy, and glaucoma are the leading causes of blindness and low vision in the US. Other common eye disorders reported in the country include amblyopia and strabismus. With aging populations and the increased frequency of younger adults receiving refractive surgeries, dry eye is expected to affect as many as 2.79 million men in the US by 2030.

The US is the largest and fastest-growing country in the North America eye drops market. The market in this country is ascribed to the increasing incidence of dry eye disease among people. Various companies offering different eye drops and lenses to treat dry eye condition have presence in the US. Also, the rising healthcare expenditure favors the growth of the North America eye drops market in the US.

North America Eye Drops Market Revenue and Forecast to 2030 (US$ Million)

North America Eye Drops Market Segmentation

The North America eye drops market is segmented into type, application, purchase mode, and country.

Based on type, the North America eye drops market is segmented into antibiotics, artificial tears, hormones, and others. The antibiotics segment held the largest share of the North America eye drops market in 2022.

Based on application, the North America eye drops market is segmented into eye diseases, eye care, and others. The eye diseases segment held the largest share of the North America eye drops market in 2022. The eye diseases segment is further segmented into dry eye, glaucoma, cataract, and others.

Based on purchase mode, the North America eye drops market is segmented into OTC and prescription. The prescription segment held a larger share of the North America eye drops market in 2022.

Based on country, the North America eye drops market is segmented into the US, Canada, and Mexico. The US dominated the North America eye drops market in 2022.

AbbVie Inc, Akorn Operating Company LLC, Alcon AG, Bausch & Lomb Inc, Pfizer Inc, Prestige Consumer Healthcare Inc., Rohto Pharmaceutical Co Ltd, and Similasan Corp are some of the leading companies operating in the North America eye drops market.

Reasons to Buy:

Table Of Contents

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. North America Eye Drops Market Landscape

5. North America Eye Drops Market - Key Industry Dynamics

6. Eye Drops Market - North America Market Analysis

7. North America Eye Drops Market - Revenue and Forecast to 2030 - by Type

8. North America Eye Drops Market - Revenue and Forecast to 2030 - by Application

9. North America Eye Drops Market - Revenue and Forecast to 2030 - by Purchase Mode

10. North America Eye Drops Market - Revenue and Forecast to 2030 - Country Analysis

11. North America Eye Drops Market-Industry Landscape

12. Company Profiles

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â